Tag
This review synthesizes emerging evidence demonstrating robust effectiveness of RSV vaccination in reducing hospitalization, death, and severe outcomes among elderly nursing home residents during the vaccine’s inaugural season.
A large-scale VSD study found that prenatal vaccination with bivalent prefusion F RSV vaccine is generally safe, showing no increased risk for preterm birth, stillbirth, or small-for-gestational-age births but a slight increase in hypertens
A comprehensive meta-analysis of 121.8 million individuals confirms that RSV vaccines are approximately 75% effective against hospitalization and severe disease in older adults, despite low global uptake and a rare risk of Guillain-Barré sy
This review analyzes the long-term effectiveness of RSV vaccination among US Veterans, revealing significant protection against severe outcomes that wanes over two seasons, particularly in immunocompromised populations.
In a multicentre test‑negative study of 1006 adults aged 75–79 in England, a bivalent RSV pre‑F vaccine reduced RSV‑associated hospitalisation by 82% overall and protected against severe disease and exacerbations of chronic heart and lung d
In a prespecified secondary analysis of the DAN‑RSV randomized trial, the bivalent RSV prefusion F vaccine showed comparable effectiveness against RSV‑related respiratory hospitalizations in adults ≥60 years with and without pre‑existing at
RSV vaccines demonstrate substantial effectiveness and acceptable safety profiles in adults aged ≥60, with diminished effectiveness in immunocompromised subgroups and a low, statistically significant increased risk of Guillain-Barré syndrom
A systematic review supports the continued safety and effectiveness of Covid-19, RSV, and influenza vaccines for the upcoming 2025-2026 season, highlighting detailed vaccine efficacy, safety profiles, and recommendations for at-risk populat
The AS01E-adjuvanted RSVPreF3 OA vaccine demonstrates robust efficacy against RSV-related lower respiratory tract disease over three seasons in adults aged 60+, with a favorable safety profile and promising immunogenicity findings.
This study assesses the safety and immune response of an adjuvanted RSVPreF3 vaccine in adult allogeneic hematopoietic cell and lung transplant recipients, highlighting modest antibody responses but robust CD4+ T-cell activation, supporting
A large multicenter study demonstrates that a single dose of RSV vaccine reduces hospitalization risk by 58% among adults aged 60+, with lower effectiveness in immunocompromised and cardiovascular patients.
The DAN-RSV trial demonstrates that RSV vaccination significantly lowers all-cause cardiorespiratory hospitalizations among older adults, suggesting vaccines may reduce infection-triggered cardiovascular complications and benefit chronic di
This phase I/II trial demonstrates that the live-attenuated intranasal RSV vaccine (RSVt) is immunogenic and well-tolerated in infants and toddlers, offering a potential new preventive option against RSV infection.
